The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial
In this video, Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, briefly comments on the findings of the ongoing Phase IIIb MAXILUS study (NCT06045689), which is being conducted to evaluate whether luspatercept treatment can be initiated at the maximum-approved dose in patients with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
